TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03952611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Using an instrument called colonoscope which is used to detect colonic polyps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Using an instrument called colonoscope which is used to detect colonic polyps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Using an instrument called colonoscope which is used to detect colonic polyps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: distal Cap
Description: Using an instrument called cap at end of colonoscope which is used to straighten colon folds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff
Description: Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
Study: NCT02870387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Care with Inpatient consultation
Description: Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Inpatient Care
Description: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
Study: NCT04477915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auxiliary respiratory exercises
Description: Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
Study: NCT02978209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7.5 %
Description: Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
Study: NCT02392494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1075
Description: MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1075
Description: MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
Study: NCT02491281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Study: NCT00143559

Intervention type: DRUG
Group type: OTHER
Intervention: Systematic chemotherapy and antibodies
Description: Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic stem cell transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device

Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi CliniMACS
Description: Miltenyi Biotec CliniMACS stem cell selection device
Study: NCT02518100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration
Description: Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration
Description: Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
Study: NCT00436319

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Duration of GnRH agonist downregulation
Description: This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history.
Study: NCT01684891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: multiple doses of RG1662
Study: NCT03489681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62).
Study: NCT00425477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study: NCT01005446

Intervention type: DEVICE
Intervention: Encore Reverse Shoulder Prosthesis (RSP®)
Description: The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
Study: NCT00476996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Oral repeating dose
Study: NCT00450619

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Samarium Sm 153 lexidronam pentasodium
Description: 1 mCi/Kg given intravenous (IV)over 1 minute on day 8.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Samarium Sm 153 lexidronam pentasodium
Description: 1 mCi/Kg given intravenous (IV)over 1 minute on day 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 100 mcg/injection x 4 days given subcutaneously
Study: NCT00476996

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leflunomide
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose (200mg)
Study: NCT04232995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercises
Description: General Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Exercises
Description: General Exercises
Study: NCT00476996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose (500mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study: NCT03121118

Intervention type: OTHER
Intervention: Scan Opportunity
Description: Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
Study: NCT01504048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Indigo-Carmine Chromoendoscopy
Description: Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
Study: NCT03153020

Intervention type: OTHER
Intervention: Patients with stroke or transient ischemic attack
Description: Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
Study: NCT03874754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Technology-Enhance Home-based exercise program (iHBE)
Description: The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
Study: NCT01958879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ringer with corticosteroid
Description: 200 mL Ringer solution+1mg dexamethasone after finishing the irrigation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ringer without corticosteroid
Description: 200 mL Ringer solution
Study: NCT03805555

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Pulmonary vein isolation by radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Pulmonary vein isolation by cryoballoon ablation
Study: NCT02770313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
Study: NCT01178346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX vaccine
Description: NicVAX vaccine given 6 times over 6 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine given 6 times over 6 months
Study: NCT00707343

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLT-PET Imaging
Description: radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
Study: NCT00424294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-195,543
Description: CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
Study: NCT01333306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Study: NCT01896388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifenprodil Tartrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00450619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia-TRICOM vaccine
Description: 2 x 10\^8 PFU given subcutaneously on day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fowlpox-TRICOM vaccine
Description: 1 x 10\^9 PFU given subcutaneously on days 15 and 29
Study: NCT01688076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Forehead will be injected with Botox.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Forehead will be injected with Botox.
Study: NCT04078880

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron plus ascorbic acid
Description: A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
Study: NCT02287909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Swiching from ticagrelor to clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Swiching from ticagrelor to clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Swiching from ticagrelor to clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Continue treatment with ticagrelor
Study: NCT03279211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 894 Fonterra
Description: 30 g of protein powder diluted in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zein Sigma-Aldrich W555025
Description: 30 g of protein powder diluted in water

Intervention type: OTHER
Group type: OTHER
Intervention: Protein-free test-meal
Description: No protein included in the drink made of water and flavour/sugar
Study: NCT00874003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirtazapine
Description: oral tablet, 30 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet, 1 daily
Study: NCT03018808

Intervention type: OTHER
Intervention: Minimal questionnaire
Description: The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.

Intervention type: OTHER
Intervention: Medical interview
Description: Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.

Intervention type: OTHER
Intervention: Medical interview
Description: Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
Study: NCT00680628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase + Enoxaparin
Description: Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline + Enoxaparin
Description: Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
Study: NCT01658553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
Study: NCT01864265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered according to the label of the biological

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered according to the label of the biological
Study: NCT00820989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin, Lipopolysaccharide, LPS
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
Study: NCT01448538

Intervention type: DRUG
Intervention: Anti-VEGF injections
Description: All Anti-VEGF injections approved for the German market, dosages as defined by doctors
Study: NCT03027674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% nifedipine cream
Description: Topical treatment for Raynaud

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% sildenafil cream
Description: Topical treatment for Raynaud
Study: NCT01452477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tanshinone
Description: tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tanshinone placebo
Description: placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Study: NCT00827177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with ARQ 197 in combination with sorafenib
Description: Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid).
Study: NCT00437398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Transplant
Description: Purified pancreatic islets